Findings showed 31.7% of patients receiving ixekizumab and tirzepatide achieved both ACR50 and at least 10% weight loss vs 0.8% on ixekizumab monotherapy. Topline data were announced from a phase 3b ...

Add Yahoo as a preferred source to see more of our stories on Google. Lynk Pharmaceuticals' next generation JAK inhibitor Lynk Pharmaceuticals has posted positive topline results from a Phase III ...

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting the prospects of a candidate designed to avoid the adverse events caused by ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with concomitant ixekizumab and tirzepatide met PsA and weight reduction endpoints. Safety data ...

On Thursday, Eli Lilly and Co. (NYSE: LLY) revealed topline results from the novel TOGETHER-PsA open-label Phase 3b trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide ...

Lilly’s Taltz (ixekizumab) and Mounjaro (tirzepatide) used together demonstrated significant efficacy in adults with active psoriatic arthritis and obesity or overweight In a first-of-its-kind Phase ...

As evidence of tirzepatide’s efficacy mounts across a range of cardiometabolic conditions, Eli Lilly has shown that taking the incretin medicine alongside another of its drugs, Taltz, could lead to ...

At 36 weeks, the TOGETHER-PsA study met its primary endpoint of 50% improvement in psoriatic arthritis (PsA) activity based on ACR50 in addition to ≥10% weight reduction with concomitant Taltz and ...

CHICAGO -- Plaque psoriasis drug deucravacitinib (Sotyktu) now looks likely to win a psoriatic arthritis (PsA) indication in the near future, with results after 1 year reported here from one of its ...

Twelve years ago, Canadian writer Christine Estima was broke and living in England, when she came across a journalism fellowship named for Milena Jesenská. Estima had never heard of her before, so she ...

Find out the average market price range for this vehicle. # This number is operated by CarsGuide. You will be redirected to the seller, who will be provided with your number.

UCB has announced new three-year data from phase 3 trials and their open-label extensions investigating BIMZELX (bimekizumab) in psoriatic arthritis and axial spondyloarthritis. The results, presented ...